Objective: This study aimed at comparing precursors of endogenous corticosteroid production in patients with primary adrenal insufficiency and in secondary adrenal insufficiency. Results: Compared to controls, progressively lower concentrations of the glucocorticoid precursors 11-deoxycortisol, 11-deoxycorticosterone and corticosterone concentrations were found in patients with secondary adrenal insufficiency on lower hydrocortisone dose, secondary adrenal insufficiency on higher hydrocortisone dose and primary adrenal insufficiency, respectively. Half of the primary adrenal insufficient patients showed evidence of residual endogenous cortisol or aldosterone synthesis, as determined by quantifiable 11-deoxycortisol, 11-deoxycorticosterone and corticosterone conce ntrations. In secondary adrenal insufficient patients with higher endogenous cortisol production, as indicated by 11-deoxycortisol concentrations above the median, no increased cortisol exposure was observed both by plasma pharmacokinetic parameters and 24-hour free cortisol excretion in urine.
| INTRODUC TI ON
Patients with primary adrenal insufficiency (PAI) due to autoimmune adrenalitis are thought to have no adrenal cortical function after long-standing disease as a consequence of progressive destruction of the adrenal gland. This notion comes from autopsy reports in which the adrenal glands were found to be small after long-standing disease, with a capsule that was thickened and fibrotic and a cortex that was completely destroyed, although in some cases a few small clusters of adrenocortical cells were found surrounded by lymphocytes. 1 The previous research has shown that the development of adrenal insufficiency progresses through different stages whereby adrenocortical autoantibodies correlate with the degree of adrenal dysfunction. 2, 3 This suggests that adrenal insufficiency is always the inevitable end result, but interestingly some cases of (partial) recovery of adrenal function in a patient with autoimmune Addison's disease have been described. [4] [5] [6] [7] Further, in a cross-sectional study by
Smans and Zelissen performed among 27 patients with long-standing autoimmune Addison's disease 10 patients were found to have detectable cortisol at the end of synacthen testing. 8 Although none of them showed (partial) recovery of adrenal function, their findings clearly indicate that in one third of patients with long-standing disease, some residual adrenal function was still present. Even though very rare, testing for residual function may have far reaching consequences because Gan and co-workers found that the treatment with tetracosactide improved adrenal function in one patient.
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Patients with secondary adrenal insufficiency (SAI) have an insufficient production of ACTH due to pituitary injury. The adrenal glands therefore lack the stimulus for adequate cortisol production and become atrophic. At the time of the diagnosis of both PAI and SAI, the early morning cortisol or the stimulated cortisol is very low, but often still measurable. The clinical significance of this residual production is unknown. It can be speculated to reduce the requirements of hormone replacement, affect quality of life, or influence hospital admission rates for Addisonian crisis and even mortality.
Once the diagnosis of PAI or SAI is established, patients are rapidly replaced to compensate for the loss of hormone production. Patients suffering from PAI and SAI require cortisol replacement, commonly given as hydrocortisone (HC) tablets. In addition, patients with PAI need fludrocortisone replacement as substitute for aldosterone.
These therapies are lifelong. Interestingly, some investigators found that recovery of the adrenal function was not uncommon in secondary adrenal insufficiency even after a median of nearly 2 years.
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Few studies have addressed the residual endogenous cortisol production in long-standing adrenal insufficiency during substitution therapy. This is difficult because the chemical composition of hydrocortisone tablets and endogenous cortisol is identical, and therefore, usually the strategy is chosen to temporarily withdraw hydrocortisone substitution. Alternatively, this problem can be circumvented by using stable isotope dilution/mass spectrometry, but these techniques are difficult and only a few research centres are equipped to do such studies. 11, 12 A candidate approach to determine residual endogenous cortisol or aldosterone production may be the measurement of precursors of these corticosteroids. To explore this option,
we recently developed a LC-MS/MS assay capable of measuring not only cortisol and cortisone in one run but also several precursor corticosteroids including 11-deoxycortisol (11S), 11-deoxycorticosterone (11DOC) and corticosterone (B) concentrations. This creates the possibility to routinely map the underlying function of the adrenal cortex in patients on hydrocortisone substitution and to gain further insight in its clinical consequence. The aim of this study was to assess the applicability of these techniques in estimating the residual function of the adrenal cortex in patients with adrenal insufficiency.
| ME THODS

| Study design
In this study, we compared patients with primary adrenal insufficiency and their controls from a cross-sectional, single-centre, casecontrol study with patients with secondary adrenal insufficiency from a randomized double-blind crossover study.
| Ethical considerations
In both studies, ethical approval was obtained from the local ethics committee. The study was approved by the University Medical Center Groningen, the Netherlands and Sahlgrenska University Hospital, Gothenburg, Sweden. Informed consent was obtained from all participants before any elements of the study were performed.
The study was conducted according to the latest Declaration of Helsinki. Compliance with study medication was assessed as described.
| Subjects
14 After each treatment period, blood sample drawing 1 hour after ingestion of the morning dose of hydrocortisone was done and 24-hour urine collection was performed. The initial study population existed 47 patients that completed both study periods.
14 For present analysis, samples of 19 patients were available.
| Exposure to and pharmacokinetics of hydrocortisone
In patients with secondary adrenal insufficiency, estimations of the individual pharmacokinetic parameters were calculated as described in detail elsewhere. 15 In short, the Kinpop module of MwPharm version 3.81 was used to calculate a one-compartment and two-compartment population model for plasma total cortisol. The models were calculated using an iterative two-stage It is not possible to determine (without the use of stable isotopes)
whether cortisol in plasma is solely present as the consequence of hydrocortisone substitution or as a consequence of both residual endogenous cortisol production and substitution therapy. We therefore studied cortisol exposure and pharmacokinetics to estimate whether higher producers of 11-deoxycortisol (suggestive of higher residual endogenous cortisol production) contributed to more cortisol exposure or a longer cortisol half-life.
| Laboratory analysis
Cortisol (F), cortisone (E), 11-deoxycortisol (11S), corticosterone (B)
and 11-deoxycorticosterone (11DOC) were measured by isotope dilution liquid chromatography tandem mass spectrometry (LC-MS/ MS). The measurement of these steroids in plasma was performed essentially as described by Hawley et al, using cortisol-D4, E-D7, 11S-13C3, 21S-D4, B-D4, and 11DOC-13C3 as internal standard.
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In short, 200 µL of plasma was used, and isotope labelled internal standards were added and incubated for 10 minutes. Samples were extracted using a 400 µL supported liquid extraction plate (Biotage).
Samples were eluted with methyl tert-butyl ether. The resulting eluate was evaporated and reconstituted in 200 µL 40% methanolwater (v/v) and vortex-mixed. 40 μL was injected on the online solidphase extraction system (Acquity Online SPE Manager, Waters), and the sample was extracted using a XBridge C18 cartridge (Waters). A Kinetex Biphenyl 100 × 2.1 mm column with a 2.6 μm particle size Urinary free cortisol was also measured using isotope dilution LC-MS/MS, as previously described. 
| Statistics
Data are presented as mean ± standard deviation or median (interquartile range) when appropriate. Normality of the data was checked using QQ-plots and histograms. Parametric statistics were used between groups for most of the variables. However, differences in the pharmacokinetic parameters for plasma total cortisol and urinary free cortisol between groups separated by the median of 11-deoxycortisol were assessed using the Mann-Whitney U test.
This test was separately used for both the lower and the higher dose of HC.
| RE SULTS
| Subject characteristics
Twenty patients with PAI with matched controls and 19 with SAI were compared. Clinical characteristics are shown in Table 1 . Age and age at diagnosis was not different between groups. The group of PAI consisted of more women than the SAI group (75% vs 53%). Weight, BMI and waist were all significantly higher in the SAI patients. Patients with PAI used a HC morning dose and total daily dose that were intermediate between the lower and higher HC dose of SAI patients. When corrected for body weight, the higher dose of hydrocortisone in SAI was similar to the dose of the PAI patients.
| 11-deoxycortisol, corticosterone and 11-deoxycorticosterone
Quantifiable amounts of 11-deoxycortisol or corticosterone or 11-deoxycorticosterone were present in 100% of controls, in 94.7% of patients with SAI and in 50% of patients with PAI. The individual percentages for each of these compounds for the study groups are given in Table 2 
| Exposure to and pharmacokinetics of hydrocortisone in SAI patients
Patients with SAI who had 11-deoxycortisol concentrations below the median on either the lower dose or the higher dose of HC showed no differences in pharmacokinetic parameters of HC, especially not elimination half-life (t ½ ) and 24-hour cortisol exposure in plasma (AUC 24h). In addition, urinary 24-hour cortisol excretion was also not different in these patient groups (Table 3) . 
TA B L E 1 Clinical characteristics of study patients
Controls (n = 20) Primary adrenal insufficiency patients (n = 20)
Secondary adrenal insufficiency patients (n = 19) P-Value
| D ISCUSS I ON
This study demonstrates that adrenal cortisol production is likely to continue in almost all patients with SAI. Interestingly, even in half of the PAI patients, precursors of cortisol and aldosterone were quantifiable. Remarkable is that all patients had long-standing disease on average 15-20 years. Our study points to interesting novelties in physiology both in PAI and SAI. In PAI patients, the presumed autoimmune destruction of the adrenal gland may not be complete in a substantial number of patients who show residual functioning of adrenal cortical tissue, albeit at a very low level. And in SAI patients, the adrenal glands show evidence of cortisol production, even after long-standing absence of significant amounts of ACTH and in the presence of negative feedback provided by exogenous hydrocortisone. Based on the duration of the pituitary disease, which was between 10 and 20 years in our patients, this is a new finding. It is well-known that duration of more than 30 days after onset of ACTH deficiency leads to adrenal atrophy. 18 However, results of our study indicate that this functional atrophy appears not to be complete in long-standing disease. Altogether, our results show that some residual functioning of the adrenal cortical gland is common in adrenal insufficiency, especially in secondary adrenal insufficiency.
Residual adrenocortical functioning during hydrocortisone is not frequently studied during substitution therapy. Usually a strategy is chosen to temporarily withdraw hydrocortisone treatment followed by measurement of an early morning cortisol or by dynamic testing, 8 but this is usually done to confirm or reject the diagnosis of adrenal insufficiency preferentially at an early stage after disease onset.
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Hydrocortisone withdrawal is possible and may certainly be of value. However, by this approach we obviate the need for withdrawal. It opens the possibility to routinely map the underlying function of the adrenal cortex in patients on hydrocortisone substitution at any moment visiting the endocrine outpatient clinic. In addition, withdrawal of hydrocortisone is not clinical practice during long-term therapy, as is the case in our patient group who were on approximately 10-20 years after their diagnosis of adrenal insufficiency.
Techniques involving stable isotopes may give insight in patients with adrenal insufficiency, but these studies have not been performed with the focus on residual endogenous cortisol production.
In addition, this technique is not a tool for daily clinical practice and only feasible in specialized laboratories. In contrast, plasma steroid profiling by means of LC-MS/MS is a newly developed technique available since a few years and has been used for the evaluation of secreting adrenal adenomas. [20] [21] [22] Mass spectrometry is an efficient TA B L E 2 Percentages of patients and controls with quantifiable amounts of 11-deoxycortisol, 11-deoxycorticosterone and corticosterone and specific utility superior in this context to the cumbersome immuno-assays and without disturbing cross-reactivity. 21, 23 We developed a LC-MS/MS that combines a low LOQ for all measured steroids (in the low picomolar range) and short retention time (Table   S1 ), making it possible to measure multiple samples in a short period of time. Another strength of the present study is the pharmacokinetic analysis under two HC dose conditions. In addition, urinary free cortisol was taken into account. Thus, several markers of cortisol exposure were available to assess if residual endogenous cortisol production adds to total cortisol exposure in these patients.
F I G U R E 1 Limit of quantification (LOQ). Individual data and the median are plotted
Evidence of production of cortisol precursors in adrenal insufficiency may have interesting implications. For example, low concentrations of 11-deoxycortisol or corticosterone may affect quality of life or cognition. In agreement with this, Nixon and co-workers have shown that corticosterone rather than cortisol may be the primary glucocorticoid for the brain, as a consequence of tissue-specific expression of transmembrane exporters of corticosteroids. 24 In addition,
Schweitzer found that 11-deoxycortisol to cortisol ratios were different in depressed patients when compared to normal volunteers. We conclude that cortisol synthesis is ongoing in SAI patients based on concentrations of 11-deoxycortisol, albeit at very low levels because no increase total cortisol exposure was observed in SAI patients with higher 11-deoxycortisol concentrations. This seems plausible, but additional data validated against other methods in healthy volunteers and patients are needed to gain further insight in this. However, when looking at the absolute concentrations of 11-deoxycortisol, which appears to be <1/1000th of the normal cortisol concentrations at 9 am, one comes to similar conclusions.
In conclusion, adrenal corticosteroid production is likely to continue during treatment in a considerable percentage of patients with PAI and in almost all patients with SAI. In patient with SAI, the higher doses of HC suppressed 11-deoxycortisol concentration, suggesting feedback inhibition of endogenous cortisol production. Whether residual cortisol production in adrenal insufficiency has clinical consequences remains to be determined.
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